Englander Israel A's Form 4 filing
Faeth Therapeutics, Inc. (FTH) · filed May 15, 2026
- Accession no.
- 0001104659-26-062603
- Filed
- May 15, 2026, 4:22 PM ET
- Trade date
- Mar 26-30, 2026
- Filing delay
- 50 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 17 non-derivative transactions and 0 derivative transactions. Open-market purchases total $818.3K. Open-market sales total $89.4K. It was filed 50 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Englander Israel ACIK 0001017456 | 10% Owner |
| Millennium Management LLCCIK 0001273087 | 10% Owner |
| Millennium Group Management LLCCIK 0001446830 | 10% Owner |
| Ics Opportunities II LLCCIK 0001783647 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Common Stock | PPurchaseAcquired | +778 | $27.23 | +$21,182.37 | 131,370 | Indirect | |
| Mar 26, 2026 | Common Stock | PPurchaseAcquired | +1,327 | $27.95 | +$37,085.27 | 131,370 | Indirect | |
| Mar 26, 2026 | Common Stock | PPurchaseAcquired | +2,601 | $28.85 | +$75,048.99 | 131,370 | Indirect | |
| Mar 26, 2026 | Common Stock | PPurchaseAcquired | +1,025 | $29.98 | +$30,728.27 | 131,370 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −583 | $26.88 | −$15,670.87 | 131,370 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −1,274 | $28.69 | −$36,548.77 | 131,370 | Indirect | |
| Mar 27, 2026 | Common Stock | PPurchaseAcquired | +10,643 | $26.29 | +$279,839.59 | 142,360 | Indirect | |
| Mar 27, 2026 | Common Stock | PPurchaseAcquired | +4,384 | $27.28 | +$119,606.92 | 142,360 | Indirect | |
| Mar 27, 2026 | Common Stock | PPurchaseAcquired | +294 | $28.13 | +$8,270.25 | 142,360 | Indirect | |
| Mar 27, 2026 | Common Stock | SSaleDisposed | −469 | $26.77 | −$12,552.88 | 142,360 | Indirect | |
| Mar 27, 2026 | Common Stock | SSaleDisposed | −36 | $27.37 | −$985.28 | 142,360 | Indirect | |
| Mar 30, 2026 | Common Stock | PPurchaseAcquired | +2,992 | $25.08 | +$75,034.57 | 145,678 | Indirect | |
| Mar 30, 2026 | Common Stock | PPurchaseAcquired | +4,995 | $25.99 | +$129,820.05 | 145,678 | Indirect | |
| Mar 30, 2026 | Common Stock | PPurchaseAcquired | +1,176 | $26.70 | +$31,399.2 | 145,678 | Indirect | |
| Mar 30, 2026 | Common Stock | PPurchaseAcquired | +370 | $27.68 | +$10,241.6 | 145,678 | Indirect | |
| Mar 30, 2026 | Common Stock | SSaleDisposed | −518 | $25.85 | −$13,390.35 | 145,678 | Indirect | |
| Mar 30, 2026 | Common Stock | SSaleDisposed | −370 | $27.68 | −$10,241.6 | 145,678 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.